{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:45:07Z","timestamp":1786981507672,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100024603","name":"Blue Earth Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024603","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11060-025-05146-2","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:49:13Z","timestamp":1751352553000},"page":"549-560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Study of 18\u00a0F-fluciclovine PET for serial assessment of glioblastoma tumor volumes during surgery and radiotherapy"],"prefix":"10.1007","volume":"175","author":[{"given":"Samir A.","family":"Dagher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania M.M.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehbaz","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Mawlawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wintermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawid","family":"Schellingerhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Flynt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra N.","family":"Yeboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherise D.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Gule-Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"5146_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2023) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2016\u20132020. Neuro-Oncol 25:iv1\u2013iv99","journal-title":"Neuro-Oncol"},{"key":"5146_CR2","unstructured":"Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O (2023) NCCN Clinical Practice Guidelines in Oncology Central Nervous System Cancers. 12, 13, 16, 17, 18"},{"key":"5146_CR3","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3174\/ajnr.A2397","volume":"32","author":"LC Hygino da Cruz","year":"2011","unstructured":"Hygino da Cruz LC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32:1978\u20131985","journal-title":"AJNR Am J Neuroradiol"},{"key":"5146_CR4","unstructured":"Search Orphan Drug Designations and Approvals https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=465814. Accessed 12 May 2025"},{"key":"5146_CR5","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1093\/neuonc\/nov118","volume":"17","author":"N Galldiks","year":"2015","unstructured":"Galldiks N, Langen K-J, Pope WB (2015) From the clinician\u2019s point of view - What is the status quo of positron emission tomography in patients with brain tumors? Neuro-Oncol 17:1434\u20131444","journal-title":"Neuro-Oncol"},{"key":"5146_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11307-007-0115-2","volume":"10","author":"T Singhal","year":"2008","unstructured":"Singhal T, Narayanan TK, Jain V, Mukherjee J, Mantil J (2008) 11\u00a0C-l-Methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 10:1\u201318","journal-title":"Mol Imaging Biol"},{"key":"5146_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13550-018-0415-3","volume":"8","author":"EE Parent","year":"2018","unstructured":"Parent EE, Benayoun M, Ibeanu I, Olson JJ, Hadjipanayis CG, Brat DJ, Adhikarla V, Nye J, Schuster DM, Goodman MM (2018) [18F]Fluciclovine PET discrimination between high- and low-grade gliomas. EJNMMI Res 8:67","journal-title":"EJNMMI Res"},{"key":"5146_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.829050","author":"ML Scarpelli","year":"2022","unstructured":"Scarpelli ML, Healey DR, Mehta S, Quarles CC (2022) Imaging glioblastoma with 18F-Fluciclovine amino acid positron emission tomography. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.829050","journal-title":"Front Oncol"},{"key":"5146_CR9","first-page":"85","volume":"5","author":"N Tsuyuguchi","year":"2017","unstructured":"Tsuyuguchi N, Terakawa Y, Uda T, Nakajo K, Kanemura Y (2017) Diagnosis of brain tumors using amino acid transport PET imaging with 18F-fluciclovine: A comparative study with L-methyl-11\u00a0C-methionine PET imaging. Asia Ocean J Nucl Med Biol 5:85\u201394","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"5146_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0005-2736(01)00384-4","volume":"1514","author":"O Yanagida","year":"2001","unstructured":"Yanagida O, Kanai Y, Chairoungdua A et al (2001) Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta BBA - Biomembr 1514:291\u2013302","journal-title":"Biochim Biophys Acta BBA - Biomembr"},{"key":"5146_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/RLU.0000000000002610","volume":"44","author":"A Karlberg","year":"2019","unstructured":"Karlberg A, Berntsen EM, Johansen H et al (2019) 18F-FACBC PET\/MRI in diagnostic assessment and neurosurgery of gliomas. Clin Nucl Med 44:550","journal-title":"Clin Nucl Med"},{"key":"5146_CR12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s12149-016-1102-y","volume":"30","author":"A Kondo","year":"2016","unstructured":"Kondo A, Ishii H, Aoki S, Suzuki M, Nagasawa H, Kubota K, Minamimoto R, Arakawa A, Tominaga M, Arai H (2016) Phase IIa clinical study of [18F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors. Ann Nucl Med 30:608\u2013618","journal-title":"Ann Nucl Med"},{"key":"5146_CR13","first-page":"10","volume":"5","author":"T Wakabayashi","year":"2017","unstructured":"Wakabayashi T, Iuchi T, Tsuyuguchi N et al (2017) Diagnostic performance and safety of positron emission tomography using 18F-Fluciclovine in patients with clinically suspected High- or Low-grade gliomas: A multicenter phase IIb trial. Asia Ocean J Nucl Med Biol 5:10\u201321","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"5146_CR14","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.3390\/cancers14143485","volume":"14","author":"K Fatania","year":"2022","unstructured":"Fatania K, Frood R, Tyyger M et al (2022) Exploratory analysis of serial 18F-fluciclovine PET-CT and multiparametric MRI during chemoradiation for glioblastoma. Cancers 14:3485","journal-title":"Cancers"},{"key":"5146_CR15","doi-asserted-by":"crossref","unstructured":"Karschnia P, Young JS, Dono A et al (2022) Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neuro-Oncol noac193","DOI":"10.1200\/JCO.2022.40.16_suppl.2003"},{"key":"5146_CR16","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, Initiative for the S (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLOS Med 4:e296","journal-title":"PLOS Med"},{"key":"5146_CR17","doi-asserted-by":"publisher","first-page":"101727","DOI":"10.1016\/j.nicl.2019.101727","volume":"22","author":"M Visser","year":"2019","unstructured":"Visser M, M\u00fcller DMJ, van Duijn RJM et al (2019) Inter-rater agreement in glioma segmentations on longitudinal MRI. NeuroImage Clin 22:101727","journal-title":"NeuroImage Clin"},{"key":"5146_CR18","doi-asserted-by":"publisher","first-page":"41815","DOI":"10.18632\/oncotarget.16296","volume":"8","author":"EN Taylor","year":"2017","unstructured":"Taylor EN, Ding Y, Zhu S et al (2017) Association between tumor architecture derived from generalized Q-space MRI and survival in glioblastoma. Oncotarget 8:41815\u201341826","journal-title":"Oncotarget"},{"key":"5146_CR19","doi-asserted-by":"publisher","unstructured":"Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. https:\/\/doi.org\/10.3171\/jns.2001.95.2.0190","DOI":"10.3171\/jns.2001.95.2.0190"},{"key":"5146_CR20","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.ijrobp.2010.12.055","volume":"82","author":"M Werner-Wasik","year":"2012","unstructured":"Werner-Wasik M, Nelson AD, Choi W et al (2012) What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET Phantom. Int J Radiat Oncol Biol Phys 82:1164\u20131171","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5146_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12149-024-01901-z","volume":"38","author":"H Niitsu","year":"2024","unstructured":"Niitsu H, Fukumitsu N, Tanaka K et al (2024) Methyl-11\u00a0C-L-methionine positron emission tomography for radiotherapy planning for recurrent malignant glioma. Ann Nucl Med 38:305\u2013314","journal-title":"Ann Nucl Med"},{"key":"5146_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12149-021-01670-z","volume":"35","author":"T Wakabayashi","year":"2021","unstructured":"Wakabayashi T, Hirose Y, Miyake K et al (2021) Determining the extent of tumor resection at surgical planning with 18F-fluciclovine PET\/CT in patients with suspected glioma: multicenter phase III trials. Ann Nucl Med 35:1279\u20131292","journal-title":"Ann Nucl Med"},{"key":"5146_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11307-013-0693-0","volume":"16","author":"S Oka","year":"2014","unstructured":"Oka S, Okudaira H, Ono M, Schuster DM, Goodman MM, Kawai K, Shirakami Y (2014) Differences in transport mechanisms of trans-1-Amino-3-[18F]Fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with l-[Methyl-11\u00a0C]Methionine and 2-Deoxy-2-[18F]Fluoro-d-Glucose. Mol Imaging Biol 16:322\u2013329","journal-title":"Mol Imaging Biol"},{"key":"5146_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.prro.2016.03.007","volume":"6","author":"AR Cabrera","year":"2016","unstructured":"Cabrera AR, Kirkpatrick JP, Fiveash JB et al (2016) Radiation therapy for glioblastoma: executive summary of an American society for radiation oncology Evidence-Based clinical practice guideline. Pract Radiat Oncol 6:217\u2013225","journal-title":"Pract Radiat Oncol"},{"key":"5146_CR25","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","volume":"2","author":"TJ Brown","year":"2016","unstructured":"Brown TJ, Brennan MC, Li M et al (2016) Association of the extent of resection with survival in glioblastoma: A systematic review and Meta-analysis. JAMA Oncol 2:1460\u20131469","journal-title":"JAMA Oncol"},{"key":"5146_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/neuros\/nyy049","volume":"84","author":"F Gessler","year":"2019","unstructured":"Gessler F, Bernstock JD, Braczynski A, Lescher S, Baumgarten P, Harter PN, Mittelbronn M, Wu T, Seifert V, Senft C (2019) Surgery for glioblastoma in light of molecular markers: impact of resection and MGMT promoter methylation in newly diagnosed IDH-1 Wild-Type glioblastomas. Neurosurgery 84:190\u2013197","journal-title":"Neurosurgery"},{"key":"5146_CR27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3389\/fonc.2020.01087","volume":"10","author":"F Incekara","year":"2020","unstructured":"Incekara F, Smits M, van der Voort SR, Dubbink HJ, Atmodimedjo PN, Kros JM, Vincent AJPE, van den Bent M (2020) The association between the extent of glioblastoma resection and survival in light of MGMT promoter methylation in 326 patients with newly diagnosed IDH-Wildtype glioblastoma. Front Oncol 10:1087","journal-title":"Front Oncol"},{"key":"5146_CR28","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3171\/2014.7.JNS132449","volume":"121","author":"MM Grabowski","year":"2014","unstructured":"Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, Vogelbaum MA (2014) Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 121:1115\u20131123","journal-title":"J Neurosurg"},{"key":"5146_CR29","doi-asserted-by":"publisher","first-page":"852","DOI":"10.2967\/jnumed.122.264812","volume":"64","author":"A Nabavizadeh","year":"2023","unstructured":"Nabavizadeh A, Bagley SJ, Doot RK et al (2023) Distinguishing progression from pseudoprogression in glioblastoma using 18F-Fluciclovine PET. J Nucl Med 64:852\u2013858","journal-title":"J Nucl Med"},{"key":"5146_CR30","doi-asserted-by":"publisher","first-page":"13258","DOI":"10.1038\/s41598-022-16726-x","volume":"12","author":"C Taylor","year":"2022","unstructured":"Taylor C, Ekert JO, Sefcikova V, Fersht N, Samandouras G (2022) Discriminators of pseudoprogression and true progression in high-grade gliomas: A systematic review and meta-analysis. Sci Rep 12:13258","journal-title":"Sci Rep"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05146-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05146-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05146-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T06:57:52Z","timestamp":1757487472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05146-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["5146"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05146-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of The University of Texas MD Anderson Cancer Center (Protocol Number 2018\u2009\u2212\u20090869). Written informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a03.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}